259 related articles for article (PubMed ID: 37923822)
21. CD4
Franken A; Bila M; Mechels A; Kint S; Van Dessel J; Pomella V; Vanuytven S; Philips G; Bricard O; Xiong J; Boeckx B; Hatse S; Van Brussel T; Schepers R; Van Aerde C; Geurs S; Vandecaveye V; Hauben E; Vander Poorten V; Verbandt S; Vandereyken K; Qian J; Tejpar S; Voet T; Clement PM; Lambrechts D
Immunity; 2024 Mar; 57(3):541-558.e7. PubMed ID: 38442708
[TBL] [Abstract][Full Text] [Related]
22. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation.
Reyes RM; Deng Y; Zhang D; Ji N; Mukherjee N; Wheeler K; Gupta HB; Padron AS; Kancharla A; Zhang C; Garcia M; Kornepati AVR; Boyman O; Conejo-Garcia JR; Svatek RS; Curiel TJ
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849925
[TBL] [Abstract][Full Text] [Related]
23. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma.
Saito R; Sawada Y; Nakamura M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669410
[TBL] [Abstract][Full Text] [Related]
24. Hemagglutinating virus of Japan-envelope containing programmed cell death-ligand 1 siRNA inhibits immunosuppressive activities and elicits antitumor immune responses in glioma.
Sugii N; Matsuda M; Okumura G; Shibuya A; Ishikawa E; Kaneda Y; Matsumura A
Cancer Sci; 2021 Jan; 112(1):81-90. PubMed ID: 33155337
[TBL] [Abstract][Full Text] [Related]
25. Multifunctionality of CD8
Manabe K; Yamasaki O; Nakagawa Y; Miyake T; Udono H; Morizane S
J Dermatol; 2021 Aug; 48(8):1186-1192. PubMed ID: 33890340
[TBL] [Abstract][Full Text] [Related]
26. B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines.
Ji S; Lee J; Lee ES; Kim DH; Sin JI
Hum Vaccin Immunother; 2021 Jul; 17(7):1910-1922. PubMed ID: 33522416
[TBL] [Abstract][Full Text] [Related]
27. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
[TBL] [Abstract][Full Text] [Related]
28. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
[TBL] [Abstract][Full Text] [Related]
29. Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade.
Awad RM; Lecocq Q; Zeven K; Ertveldt T; De Beck L; Ceuppens H; Broos K; De Vlaeminck Y; Goyvaerts C; Verdonck M; Raes G; Van Parys A; Cauwels A; Keyaerts M; Devoogdt N; Breckpot K
Mol Ther Methods Clin Dev; 2021 Sep; 22():172-182. PubMed ID: 34485603
[TBL] [Abstract][Full Text] [Related]
30. Development of an IL-15-autocrine CD8 T-cell leukemia in IL-15-transgenic mice requires the cis expression of IL-15Rα.
Sato N; Sabzevari H; Fu S; Ju W; Petrus MN; Bamford RN; Waldmann TA; Tagaya Y
Blood; 2011 Apr; 117(15):4032-40. PubMed ID: 21304101
[TBL] [Abstract][Full Text] [Related]
31. The roles of different forms of IL-15 in human melanoma progression.
Di Matteo S; Munari E; Fiore PF; Santopolo S; Sampaoli C; Pelosi A; Chouaib S; Tumino N; Vacca P; Mariotti FR; Ebert S; Machwirth M; Haas D; Pezzullo M; Pietra G; Grottoli M; Buart S; Mortier E; Maggi E; Moretta L; Caruana I; Azzarone B
Front Immunol; 2023; 14():1183668. PubMed ID: 37334356
[TBL] [Abstract][Full Text] [Related]
32. A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.
Takeda Y; Kataoka K; Yamagishi J; Ogawa S; Seya T; Matsumoto M
Cell Rep; 2017 May; 19(9):1874-1887. PubMed ID: 28564605
[TBL] [Abstract][Full Text] [Related]
33. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
[TBL] [Abstract][Full Text] [Related]
34. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
35. A Systematic Review of the Tumor-Infiltrating CD8
Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
Front Immunol; 2021; 12():734956. PubMed ID: 34603316
[TBL] [Abstract][Full Text] [Related]
36. Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model.
Wang H; He X; Fang D; Wang X; Guan J; Shi ZW; Chen X
Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101853. PubMed ID: 34923183
[TBL] [Abstract][Full Text] [Related]
37. Development of a recombinant human IL-15·sIL-15Rα/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model.
Zhao M; Luo M; Xie Y; Jiang H; Cagliero C; Li N; Ye H; Wu M; Hao S; Sun T; Yang H; Zhang M; Lin T; Lu H; Zhu J
Biomed Pharmacother; 2019 Apr; 112():108677. PubMed ID: 30798123
[TBL] [Abstract][Full Text] [Related]
38. B7-H4 overexpression impairs the immune response of T cells in human cervical carcinomas.
Wang X; Wang T; Xu M; Xiao L; Luo Y; Huang W; Zhang Y; Geng W
Hum Immunol; 2014 Dec; 75(12):1203-9. PubMed ID: 25446402
[TBL] [Abstract][Full Text] [Related]
39. Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis.
Pittet CL; Newcombe J; Prat A; Arbour N
J Neuroinflammation; 2011 Nov; 8():155. PubMed ID: 22067141
[TBL] [Abstract][Full Text] [Related]
40. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2.
Carter L; Fouser LA; Jussif J; Fitz L; Deng B; Wood CR; Collins M; Honjo T; Freeman GJ; Carreno BM
Eur J Immunol; 2002 Mar; 32(3):634-43. PubMed ID: 11857337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
